Find a Cancer Clinical Trial for Your Child
Memorial Sloan Kettering conducts hundreds of clinical trials to improve care for people with many types of cancer. This includes more than 100 studies for children, teens, and young adults. Use this tool to browse our list of open clinical trials for young people. Each listing explains the purpose of the trial, who is eligible, and how to get more information.
New clinical trials are always opening. For more information and to find out about our latest studies, call 833-675-5437 or email us at [email protected].
-
Doctors want to know if giving emapalumab as upfront pre-treatment works well for people with severe acquired aplastic anemia (sAA). This medication is given after diagnosis, but before standard sAA treatment. In people with sAA, stem cells are destroyed and the body cannot make new blood cells.
-
Metaiodobenzylguanidine (MIBG) is a substance taken up specifically by neuroblastoma, pheochromocytoma, or paraganglioma tumor cells. MIBG can be combined with radioactive iodine (<sup>131</sup>I) in the laboratory to form the radioactive compound <sup>131</sup>I-MIBG. The <sup>131</sup>I-MIBG compound concentrates more in cancer cells than in normal cells. It may therefore deliver more radiation directly to cancer cells while sparing normal organs.
-
Researchers want to find the best schedule for giving a new vaccine to people with neuroblastoma. The people in this study have neuroblastoma that is in remission (no signs of cancer). In addition, their cancers have a strong chance of coming back (high risk). The vaccine is given with a naturally occurring substance called beta-glucan.
-
The purpose of this study is to find the highest dose of the investigational drug PC14586 that can be given in patients with solid tumors that came back or continue to grow despite prior therapy and contain a mutation in the TP53 gene. The p53 protein produced by this gene normally tells cells when to stop dividing, but when TP53 is altered (mutated), cancer may result.
-
In this study, researchers are assessing a new way to determine the best dosing of fludarabine. The people in this study are children and young adults getting CAR T-cell therapy for B-cell acute lymphoblastic leukemia (B-ALL). Their cancer has come back or keeps growing despite treatment. They will be getting a CAR T-cell therapy called tisagenlecleucel (Kymriah).
-
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
- A Phase 2 Study of Axatilimab Plus Ruxolitinib in Adults and Children With Chronic Graft-Versus-Host Disease
Full Title A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease
Purpose
With chronic graft-versus-host disease (cGVHD), healthy stem cells from a donor see the recipient’s healthy cells as foreign and attack. This commonly happens about 100 days after a stem cell transplant, but it can happen at any time.
Researchers want to see if a steroid-free approach using ruxolitinib, with or without axatilimab, works well to treat cGVHD. Ruxolitinib blocks JAK proteins, which may reduce inflammation (swelling) and immune system reactions related to GVHD. Axatilimab blocks a protein called CSF-1R that controls white blood cells which play a role in GVHD.
If you join this study, you will be randomly assigned to get one of these treatments:
- Axatilimab and ruxolitinib. Axatilimab is given intravenously (by vein) and ruxolitinib is taken orally (by mouth).
- Ruxolitinib alone.
- Corticosteroids alone (methylprednisolone or prednisone, taken orally).
Who Can Join
To join this study, there are a few conditions. You or your child must:
- Have moderate to severe cGVHD that has not yet been treated.
- Be able to walk and do routine activities for more than half the time you are awake.
- Be age 12 or older.
Contact
For more information or to see if you or your child can join this study, please call Dr. Doris Ponce’s office at 646-608-3739.
Protocol
24-318Phase
Phase II (phase 2)Disease Status
Newly DiagnosedInvestigator
Co-Investigators
Diseases
Locations
ClinicalTrials.gov ID
NCT06388564ClinicalTrials.gov
-
The purpose of this study is to find the highest dose of the investigational drug NVL-655 that can be given safely in people with advanced non-small cell lung cancer (NSCLC) or other solid tumors that contain a genetic change called an ALK gene fusion. NVL-655 is a type of drug called a tyrosine kinase inhibitor (TKI), which works by blocking proteins that fuel cancer growth. However, some cancer cells develop resistance to TKI treatment.
-
Researchers are seeking the best dose of CABA-201 to treat people with active idiopathic inflammatory myopathy (IIM). The people in this study have IIM, juvenile idiopathic inflammatory myopathy (JIIM), or myositis. With JIIM and some subtypes of IIM, B cells make the body to attack different tissues, causing inflammation and muscle weakness.
-
The purpose of this study is to find the highest dose of the drug alectinib that can be given safely in children and adolescents with solid tumors or brain and spinal cord cancers that persist after treatment and have a genetic change called an ALK gene fusion. With this gene fusion, the ALK gene attaches to part of another gene.